Fundraising Fox

Alaska Permanent Fund CorporationFull Portfolio

4 tracked investments · listed companies and verified rows first

Dynatracedynatrace.comin𝕏NYSE: DT

Dynatrace provides a platform for unified observability, security, and business data analytics across clouds and containers.

AI & Machine LearningCloud ComputingCybersecurityData & InfrastructureDeveloper ToolsEnterprise Software

John Van SicleninRick McConnell(Chief Executive Officer and Director)inJim Benson(Executive Vice President, Chief Financial Officer and Treasurer)inDan Zugelder(Executive Vice President, Chief Revenue Officer)inBernd Greifeneder(Executive Vice President, Chief Technology Officer)inStephen McMahon(Executive Vice President, Chief Customer Officer)

Co-investorsGarage CapitalRembrandt Venture PartnersSilver Lake PartnersAccolade PartnersSan Bernardino County Employees Retirement Association

Generate Biomedicinesgeneratebiomedicines.comin𝕏NASDAQ: GENBNov 2021 · $370M

Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.

AI & Machine LearningBiotechDeep TechSomerville, US

Gevorg Grigoryan(Co-Founder & Chief Technology Officer)in

Co-investorsFlagship PioneeringARCH Venture PartnersMarch Capital PartnersALTITUDE LIFE SCIENCE VENTURESNVenturesT. Rowe Price

Thomas H. Lee Partnersthl.cominFeb 2023

Celerion provides clinical pharmacology and bioanalytical services to support pharmaceutical and biotechnology companies in early-phase drug development and regulatory submissions.

BiotechHealthtechLincoln, US

Susan Thornton(Founder and Chief Executive Officer)

Co-investorsBCIKensington Capital Partners Limited

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Juno Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.